TATA India PHARMA & Healthcare Fund - G

NAV ₹33.6753 ↓ -0.06 (-0.17 %) as on 20 Aug 26

📑 Table of contents

Scheme Objective
NAV Price Chart
Returns
- Historical Returns
- Compounded Returns
Growth Of 10k Over Years
Holdings / Portfolio
All Plan & Options
Fund Manager Information
Custodians
Registrar & Transfer Agent (RTA)
Administrator Companies
Auditors

Scheme Objective

The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns.

TATA India Pharma & Healthcare Fund is a Equity - Sectoral fund launched on 28 Dec 15. It is a fund with High risk and has given a CAGR return of 12.1% since its launch. Return for 2025 was -4.9% , 2024 was 40.4% and 2023 was 36.6% .

Below is the key information for TATA India Pharma & Healthcare Fund

NAV as on 20 Aug 26	₹33.6753 ↓ -0.06 (-0.17 %)
Net Assets (AUM) as on 31 Jul 2026	₹1,541 Cr.
Launch Date	28 Dec 2015
Category	Equity - Sectoral
Rating	Not Rated
Type	Open Ended Fund
Risk	High
AMC	Tata Asset Management Limited

Alpha Ratio	-8.33
Expense Ratio	2.13 %
Sharpe Ratio	0.215
Information Ratio	-0.58
Benchmark	Not Available
Min Investment	₹5,000
Min SIP Investment	₹150
Exit Load	0-3 Months (0.25%),3 Months and above(NIL)

NAV Price Chart

Returns

Annual Compounded Returns

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 20 Aug 26

Duration	Returns
1 Month	2.1%
3 Month	6%
6 Month	13.6%
1 Year	8.3%
3 Year	18.8%
5 Year	13.5%
10 Year
15 Year
Since launch	12.1%

Historical Annual Returns

Historical performance (Yearly) on absolute basis

Year	Returns
2024	-4.9%
2023	40.4%
2022	36.6%
2021	-8%
2020	19.1%
2019	64.4%
2018	5.5%
2017	-2.6%
2016	4.7%

Growth of 10k Over Years

Date	Value
31 Jul 21	₹10,000
31 Jul 22	₹9,207
31 Jul 23	₹11,165
31 Jul 24	₹16,308
31 Jul 25	₹17,610
31 Jul 26	₹19,012

Asset Allocation

Asset Class	Value
Cash	2.55%
Equity	97.45%

Sector Allocation

Sector	Value
Health Care	92.05%
Basic Materials	4.17%
Consumer Defensive	1.23%

Top Securities Holdings / Portfolio

Holdings/Securities

Name	Global Industry	Holding	Value	Quantity
Sun Pharmaceuticals Industries Ltd (Healthcare) Equity, Since 31 Jan 16 \| SUNPHARMA	Drug Manufacturers - Specialty & Generic	9%	₹124 Cr	665,178 ↓ -57,952
Max Healthcare Institute Ltd Ordinary Shares (Healthcare) Equity, Since 31 Jul 25 \| MAXHEALTH	Medical Care Facilities	6%	₹83 Cr	732,452 ↑ 41,964
HealthCare Global Enterprises Ltd (Healthcare) Equity, Since 31 Dec 18 \| HCG	Medical Care Facilities	6%	₹80 Cr	1,280,714 ↑ 3,987
Divi's Laboratories Ltd (Healthcare) Equity, Since 30 Sep 17 \| DIVISLAB	Drug Manufacturers - Specialty & Generic	5%	₹75 Cr	113,314 ↓ -7,286
Abbott India Ltd (Healthcare) Equity, Since 30 Sep 25 \| ABBOTINDIA	Drug Manufacturers - Specialty & Generic	5%	₹72 Cr	28,453 ↑ 500
Cipla Ltd (Healthcare) Equity, Since 30 Apr 20 \| 500087	Drug Manufacturers - Specialty & Generic	5%	₹69 Cr	473,861 ↓ -38,893
Apollo Hospitals Enterprise Ltd (Healthcare) Equity, Since 31 Dec 16 \| APOLLOHOSP	Medical Care Facilities	5%	₹67 Cr	77,345
Rainbow Childrens Medicare Ltd (Healthcare) Equity, Since 31 Jul 25 \| 543524	Medical Care Facilities	4%	₹64 Cr	454,338
Dr Reddy's Laboratories Ltd (Healthcare) Equity, Since 31 Aug 18 \| DRREDDY	Drug Manufacturers - Specialty & Generic	4%	₹62 Cr	457,187 ↑ 29,071
GlaxoSmithKline Pharmaceuticals Ltd (Healthcare) Equity, Since 30 Nov 25 \| GLAXO	Drug Manufacturers - General	4%	₹60 Cr	244,875 ↑ 40,122

1 - 10 of 41

Ready to Invest?
Talk to our investment specialist

Fund Managers

Name	Since	Tenure
Rajat Srivastava	16 Sep 24	1.87 Yr.

Custodians

Company	Address
Deutsche Bank AG	1 Great Winchester Street

Registrar & Transfer Agent

Computer Age Management Services Ltd
Address	New No.10, Old No.178,,Kodambakkam High Road,,Opp. Hotel Palmgrove,,Nungambakkam
FAX	91-44-28283610
Email	enq_L@camsonline.com

Administrator Companies

Company	Address
Tata Mutual Fund	1903, B-Wing, Parinee Crescenzo,,G-Block, Bandra Kurla Complex, Bandra East Mumbai 400051

Auditors

Company	Address
Deloitte Haskins & Sells LLP	12, Dr. Annie Besant Road, Opp. Shiv Sagar Estate,,Worli
M/s BSR & Co.	KPMG House, Kamala Mills Compound,448 Senapati Bapat Marg,Lower Parel

All Plan & Options

Fund and Plan	NAV	6 Month	1 Year	3 Year	5 Year
TATA India Pharma & Healthcare Fund Normal Dividend, Reinvestment	₹32.3869 ↓ -0.05	13.44 %	8.12 %	18.74 %	13.49 %
TATA India Pharma & Healthcare Fund Normal Dividend, Payout	₹32.3869 ↓ -0.05	13.44 %	8.12 %	18.74 %	13.49 %
TATA India Pharma & Healthcare Fund Growth	₹33.6753 ↓ -0.06	13.59 %	8.27 %	18.79 %	13.52 %
Data as on 20 Aug 26

Disclaimer:
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data.

Shepard Technologies Pvt. Ltd : 1808, Solus, Hiranandani Estate, Thane, Maharashtra - 400607

AMFI Registration No. 112358 | CIN: U74999MH2016PTC282153

Mutual fund investments are subject to market risks. Please read the scheme information and other related documents carefully before investing. Past performance is not indicative of future returns. Please consider your specific investment requirements before choosing a fund, or designing a portfolio that suits your needs.

Shepard Technologies Pvt. Ltd. (with ARN code 112358) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Terms and conditions of the website are applicable.